Molecular Partners AG (MOLN)
Molecular Partners Statistics
Share Statistics
Molecular Partners has 36.87M shares outstanding. The number of shares has increased by 11.13% in one year.
| Shares Outstanding | 36.87M |
| Shares Change (YoY) | 11.13% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 10.79% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 119 |
| FTD / Avg. Volume | 1.13% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.56 and the forward PE ratio is -1.68. Molecular Partners's PEG ratio is 0.16.
| PE Ratio | -2.56 |
| Forward PE | -1.68 |
| PS Ratio | 27.8 |
| Forward PS | 1.1 |
| PB Ratio | 0.98 |
| P/FCF Ratio | -2.3 |
| PEG Ratio | 0.16 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Molecular Partners.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.31, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.31 |
| Quick Ratio | 14.31 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.04 |
| Interest Coverage | -2448.68 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $31,455.7 |
| Profits Per Employee | $-342,044.3 |
| Employee Count | 158 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -0.53% in the last 52 weeks. The beta is 0.61, so Molecular Partners's price volatility has been higher than the market average.
| Beta | 0.61 |
| 52-Week Price Change | -0.53% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 5.25 |
| Relative Strength Index (RSI) | 44.57 |
| Average Volume (20 Days) | 10,527 |
Income Statement
In the last 12 months, Molecular Partners had revenue of 4.97M and earned -54.04M in profits. Earnings per share was -1.59.
| Revenue | 4.97M |
| Gross Profit | 4.97M |
| Operating Income | -61.22M |
| Net Income | -54.04M |
| EBITDA | -51.65M |
| EBIT | -54.02M |
| Earnings Per Share (EPS) | -1.59 |
Balance Sheet
The company has 63.87M in cash and 2.44M in debt, giving a net cash position of 61.43M.
| Cash & Cash Equivalents | 63.87M |
| Total Debt | 2.44M |
| Net Cash | 61.43M |
| Retained Earnings | -246.29M |
| Total Assets | 158.53M |
| Working Capital | 143.5M |
Cash Flow
In the last 12 months, operating cash flow was -59.25M and capital expenditures -723K, giving a free cash flow of -59.97M.
| Operating Cash Flow | -59.25M |
| Capital Expenditures | -723K |
| Free Cash Flow | -59.97M |
| FCF Per Share | -1.76 |
Margins
Gross margin is 100%, with operating and profit margins of -1231.73% and -1087.38%.
| Gross Margin | 100% |
| Operating Margin | -1231.73% |
| Pretax Margin | -1087.34% |
| Profit Margin | -1087.38% |
| EBITDA Margin | -1039.18% |
| EBIT Margin | -1231.73% |
| FCF Margin | -1206.66% |
Dividends & Yields
MOLN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for MOLN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 2 |